fulvestrant + goserelin + palbociclib

This is a combination regimen of three drugs used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women. - **Fulvestrant** is a selective estrogen receptor degrader (SERD) that binds to and accelerates degradation of the estrogen receptor, blocking estrogen signaling. - **Goserelin** is a luteinizing hormone-releasing hormone (LHRH) agonist that suppresses ovarian function and reduces circulating estrogen levels by downregulating pituitary gonadotropins. - **Palbociclib** is an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression from G1 to S phase, thereby inhibiting proliferation of cancer cells. This combination has demonstrated improved progression-free survival compared to endocrine therapy alone in premenopausal women with prior endocrine-resistant disease. The regimen requires ovarian suppression with goserelin for premenopausal patients to ensure effective hormonal blockade[1][3][8].

Brand names

Faslodex (fulvestrant)Zoladex (goserelin)Ibrance (palbociclib)